Recent research is shedding light on how popular weight-loss drugs like semaglutide (Wegovy, Ozempic) and tirzepatide (Mounjaro, Zepbound) differ in their effects on obesity, diabetes, and other metabolic disorders. Both drugs target the GLP-1 receptor, which helps regulate blood sugar and appetite, but tirzepatide also mimics the GIP hormone, which aids fat metabolism. Studies have shown that tirzepatide leads to greater weight loss and better prevention of type 2 diabetes than semaglutide.

In addition to weight loss, GLP-1 drugs may slow neurodegenerative diseases like Parkinson's and Alzheimer's due to their ability to reduce brain inflammation. However, research is ongoing to determine how these medications penetrate the brain and their long-term effectiveness in treating such conditions.

How 360/Health Can Help

At 360/Health, we help you stay informed about the latest treatments for obesity and diabetes. Use our app to track your health, manage your weight, and explore personalized treatment options that work best for you.

For more insights, read the full article from Nature and their reference:

• Rodriguez, P. J. et al. JAMA Intern. Med. (2024). doi:10.1001/jamainternmed.2024.2525

• Athauda, D. et al. The Lancet, 390, 1664–1675 (2017). doi:10.1016/S0140-6736(17)31585-4

• Lincoff, A. M. et al. N. Engl. J. Med., 389, 2221–2232 (2023). doi:10.1056/NEJMoa2307563

• Malhotra, A. et al. N. Engl. J. Med. (2024). doi:10.1056/NEJMoa2404881

• Véniant, M. M. et al. Nature Metabolism, 6, 290–303 (2024). doi:10.1038/s42255-023-00966-w

• Gabery, S. et al. JCI Insight, 5, e133429 (2020). doi:10.1172/JCI133429

• McGarry, A. et al. The Lancet Neurology, 23, 37–45 (2024). doi:10.1016/S1474-4422(23)00378-2